Satoshi Yajima1, Takashi Suzuki1, Yoko Oshima1, Fumiaki Shiratori1, Kimihiko Funahashi1, Shinichi Kawai2, Toshihiro Nanki3, Sei Muraoka3, Yoshihisa Urita4, Yoshihisa Saida5, Shinichi Okazumi6, Yuko Kitagawa7, Yuki Hirata7, Hirotoshi Hasegawa7, Koji Okabayashi7, Masahiko Murakami8, Takeshi Yamashita8, Rei Kato8, Hisahiro Matsubara9, Kentaro Murakami9, Yasuaki Nakajima10, Hironobu Sugita11, Martin Klammer12, Hideaki Shimada13,14. 1. Department of Surgery, School of Medicine, Toho University, Tokyo, Japan. 2. Department of Inflammation and Pain Control Research, School of Medicine, Toho University, Tokyo, Japan. 3. Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University, Tokyo, Japan. 4. General Medicine and Emergency Center, School of Medicine, Toho University, Tokyo, Japan. 5. Department of Surgery, Ohashi Medical Center, Toho University, Tokyo, Japan. 6. Department of Surgery, Sakura Medical Center, Toho University, Tokyo, Japan. 7. Department of General and Gastroenterological Surgery, Keio University Hospital, Tokyo, Japan. 8. Department of Surgery, Showa University Hospital, Tokyo, Japan. 9. Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan. 10. Esophageal Surgery, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan. 11. Roche Diagnostics K.K, Tokyo, Japan. 12. Department of Biostatistics and Advanced Data Analytics, Roche Diagnostics GmbH, Penzberg, Germany. 13. Department of Surgery, School of Medicine, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp. 14. Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
Abstract
BACKGROUND: Several recent studies suggest that serum anti-p53 antibodies (s-p53-Abs) may be combined with other markers to detect esophageal and colorectal cancer. In this study, we assessed the sensitivity and specificity of s-p53-Abs detection of a new electrochemiluminescence immunoassay (ECLIA; Elecsys anti-p53). METHODS: Elecsys anti-p53 assay was used to analyze the level of s-p53-Abs in blood sera from patients with esophageal or colorectal cancer taken before treatment. Control blood sera from healthy volunteers, patients with benign diseases, and patients with autoimmune diseases served as a reference. In addition, squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragments (CYFRA21-1) were assessed in patients with esophageal cancer, and carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 were assessed in patients with colorectal cancer. RESULTS: Samples from 281 patients with esophageal cancer, 232 patients with colorectal cancer, and 532 controls were included in the study. The median value of s-p53-Abs in control samples was < 0.02 μg/mL (range < 0.02-29.2 μg/mL). Assuming 98% specificity, the cut-off value was determined as 0.05 μg/mL. s-p53-Abs were detected in 20% (57/281) of patients with esophageal cancer and 18% (42/232) of patients with colorectal cancer. In combination with SCC-Ag and CEA, respectively, s-p53-Abs detected 51% (144/281) of patients with esophageal and 53% (124/232) of patients with colorectal cancer. CONCLUSIONS: The new s-p53-Abs assay Elecsys anti-p53 was useful in detecting esophageal and colorectal cancers with high specificity. Adding s-p53-Abs to conventional markers significantly improved the overall detection rates.
BACKGROUND: Several recent studies suggest that serum anti-p53 antibodies (s-p53-Abs) may be combined with other markers to detect esophageal and colorectal cancer. In this study, we assessed the sensitivity and specificity of s-p53-Abs detection of a new electrochemiluminescence immunoassay (ECLIA; Elecsys anti-p53). METHODS: Elecsys anti-p53 assay was used to analyze the level of s-p53-Abs in blood sera from patients with esophageal or colorectal cancer taken before treatment. Control blood sera from healthy volunteers, patients with benign diseases, and patients with autoimmune diseases served as a reference. In addition, squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragments (CYFRA21-1) were assessed in patients with esophageal cancer, and carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 were assessed in patients with colorectal cancer. RESULTS: Samples from 281 patients with esophageal cancer, 232 patients with colorectal cancer, and 532 controls were included in the study. The median value of s-p53-Abs in control samples was < 0.02 μg/mL (range < 0.02-29.2 μg/mL). Assuming 98% specificity, the cut-off value was determined as 0.05 μg/mL. s-p53-Abs were detected in 20% (57/281) of patients with esophageal cancer and 18% (42/232) of patients with colorectal cancer. In combination with SCC-Ag and CEA, respectively, s-p53-Abs detected 51% (144/281) of patients with esophageal and 53% (124/232) of patients with colorectal cancer. CONCLUSIONS: The new s-p53-Abs assay Elecsys anti-p53 was useful in detecting esophageal and colorectal cancers with high specificity. Adding s-p53-Abs to conventional markers significantly improved the overall detection rates.
Authors: Martina Müller; Martina Meyer; Tobias Schilling; Ernst Ulsperger; Thomas Lehnert; Hanswalter Zentgraf; Wolfgang Stremmel; Martin Volkmann; Peter R Galle Journal: Int J Oncol Date: 2006-10 Impact factor: 5.650
Authors: R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi Journal: Cancer Res Date: 1993-12-15 Impact factor: 12.701